Status:
COMPLETED
Rivastigmine in Mild Alzheimer's Disease, FMRI Study
Lead Sponsor:
Kuopio University Hospital
Conditions:
Alzheimer' Disease
Eligibility:
All Genders
55-85 years
Phase:
NA
Brief Summary
The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furth...
Eligibility Criteria
Inclusion
- Probable Alzheimer's disease according to the NINCDS-ADRDA criteria
- mild disease, CDR 1
- the clinician is planning to start anticholinesterase treatment
Exclusion
- cognitive impairment for other reason than Alzheimer's disease
- severe depression
- other unstable physical disease
- medal in body prevention MRI examination, claustrophobia
- cardiac pacemaker
- other significant neurologic or psychiatric disease
- contraindication for anticholinesterase treatment
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00627848
Start Date
March 1 2007
End Date
December 1 2008
Last Update
October 28 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kuopio University Hospital
Kuopio, Finland, 70211